SD Biosensor Inc (137310)
Korea Stock Exchange · Korea · prices in KRW · close of 19 Oct 2026
Key indicators
| Last close | KRW 6,920.00 |
|---|---|
| 52-week range | 5,800.00 – 9,958.83 |
| Return, 1 month / 3 months | +11.4% / +15.5% |
| Return, 1 year / 3 years | −28.6% / −43.9% |
| Trend | Below its 200-day average |
| RSI (14) | 65 |
| Volatility (1 year) | 43.7% |
| Worst drawdown (1 year) | -40.8% |
| Average daily value traded | 1,039.42M KRW |
| Dividend yield | 2.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
SD Biosensor is a South Korean medical diagnostics company that develops and manufactures in-vitro diagnostic tests. Its products include rapid test kits for infectious diseases, along with clinical chemistry and immunology testing systems used in laboratories and healthcare settings. The company supplies hospitals, diagnostic laboratories and public health organisations in Korea and in export markets around the world, and it is based in Korea.
SD Biosensor Inc trades under the code 137310 on the Korea Stock Exchange in Korea, with its price quoted in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
SD Biosensor Inc (137310) trades on the Korea Stock Exchange in Korea. It last closed at KRW 6,920.00 on 19 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 461 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 28.6% and over the last three months it rose 15.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.3% | ||
| From 52-week high | -29.6% | ||
| Momentum | 50 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 15.5% | ||
| 6-month return | -15.6% | ||
| 12-month return, skipping the last month | -35.9% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 43.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.8% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1,039.42M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.9% | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.8% |
|---|---|
| 1 month | +11.4% |
| 3 months | +15.5% |
| 6 months | −15.6% |
| 1 year | −28.6% |
| 3 years | −43.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 6,311.00 / 7,388.42 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 264.67 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Mar 2026 | KRW 200.0000 |
| 27 Dec 2024 | KRW 200.0000 |
| 28 Dec 2022 | KRW 290.0000 |
| 29 Jun 2022 | KRW 700.0000 |
| 29 Dec 2021 | KRW 1,266.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.